Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000186159 | SCV000239185 | pathogenic | not provided | 2024-03-05 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 23379544, 26828774, 15714519, 34178604) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000022324 | SCV000698151 | pathogenic | Renal carnitine transport defect | 2017-05-01 | criteria provided, single submitter | clinical testing | Variant summary: The SLC22A5 c.458_459delTG (p.Val153Alafs) variant results in a premature termination codon, predicted to cause a truncated or absent SLC22A5 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. A truncation downstream of this position, c.760C>T (p.Arg254X), has been classified as pathogenic by our laboratory. This variant is absent in 121412 control chromosomes. The variant of interest has been reported in multiple compound heterozygous affected individual via a publication (Dobrowolski_2005) and a database (ARUP). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as "likely pathogenic/pathogenic." Taken together, this variant has been classified as pathogenic. |
Eurofins Ntd Llc |
RCV000186159 | SCV000704164 | pathogenic | not provided | 2016-12-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000022324 | SCV000937220 | pathogenic | Renal carnitine transport defect | 2025-01-29 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val153Alafs*41) in the SLC22A5 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC22A5 are known to be pathogenic (PMID: 9916797). This variant is present in population databases (rs386134195, gnomAD 0.004%). This premature translational stop signal has been observed in individual(s) with primary carnitine deficiency (PMID: 15714519). ClinVar contains an entry for this variant (Variation ID: 25376). For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV000186159 | SCV001247711 | pathogenic | not provided | 2018-12-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000022324 | SCV002055804 | pathogenic | Renal carnitine transport defect | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000022324 | SCV002813735 | pathogenic | Renal carnitine transport defect | 2024-05-10 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000022324 | SCV004201274 | pathogenic | Renal carnitine transport defect | 2024-03-26 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000022324 | SCV000220438 | pathogenic | Renal carnitine transport defect | 2018-02-26 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000022324 | SCV001462803 | pathogenic | Renal carnitine transport defect | 2020-09-16 | no assertion criteria provided | clinical testing |